Journal of Natural Remedies

Open Access Open Access  Restricted Access Subscription Access

Antiviral Activity of AV-001 against Influenza and Three Common Cold Viruses


Affiliations
1 Microbiotest, Division of Microbac Laboratories, Inc. 105 Carpenter Drive, Sterling, Va 20164, Vanuatu
 

AV-001 is a dietary supplement; it is used as a throat and nose spray composed of natural ingredients, including Sambucus nigra (European elder) and eucalyptus with 1, 8-cineole. The aim of this study was to evaluate the antiviral activity of AV-001 against the pathogenic viruses human influenza A viruses H1N1 and H7N9, respiratory syncytial virus, rhinovirus, human coronavirus, and adenovirus. Antiviral activity was evaluated by reduction of the viral-induced cytopathic effect; AV-001 was assessed against a challenge virus in suspension, inoculated onto host cells, and assayed for infectious viral load.AV-001 inactivated human influenza A viruses H1N1 and H7N9, respiratory syncytial virus, rhinovirus, and human coronavirus, by ³7.17 Log10, ³6.42 Log10, ³4.72 Log10, ³4.35 Log10 and ³3.92 Log10, respectively. Thus, AV-001 exhibited strong and broad-spectrum antiviral activities and may represent an effective treatment or preventive agent for respiratory viral infection by inactivating the viruses upon their entry into the body.
Font Size

User

Notifications
JOURNAL COVERS
  

Abstract Views: 299

PDF Views: 120




  • Antiviral Activity of AV-001 against Influenza and Three Common Cold Viruses

Abstract Views: 299  |  PDF Views: 120

Authors

S. Steve Zhou
Microbiotest, Division of Microbac Laboratories, Inc. 105 Carpenter Drive, Sterling, Va 20164, Vanuatu

Abstract


AV-001 is a dietary supplement; it is used as a throat and nose spray composed of natural ingredients, including Sambucus nigra (European elder) and eucalyptus with 1, 8-cineole. The aim of this study was to evaluate the antiviral activity of AV-001 against the pathogenic viruses human influenza A viruses H1N1 and H7N9, respiratory syncytial virus, rhinovirus, human coronavirus, and adenovirus. Antiviral activity was evaluated by reduction of the viral-induced cytopathic effect; AV-001 was assessed against a challenge virus in suspension, inoculated onto host cells, and assayed for infectious viral load.AV-001 inactivated human influenza A viruses H1N1 and H7N9, respiratory syncytial virus, rhinovirus, and human coronavirus, by ³7.17 Log10, ³6.42 Log10, ³4.72 Log10, ³4.35 Log10 and ³3.92 Log10, respectively. Thus, AV-001 exhibited strong and broad-spectrum antiviral activities and may represent an effective treatment or preventive agent for respiratory viral infection by inactivating the viruses upon their entry into the body.